Unknown statusInterventionalPhase 4Last updated Feb 9, 2017

Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel

Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing "One-stop" Hybrid Coronary Revascularization

Overview

ClinicalTrials.gov ID: NCT02513004
Lead Sponsor: Yongjian WuOTHER
Brief Summary: This study is designed to test the hypothesis that the onset of the antiplatelet effect 90mg-first-dose of ticagrelor will be more rapid and greater than 300mg-loading-dose of clopidogrel evaluated by P2Y12 reaction units measured by Verify NowTM P2Y12 assay at 1 hour in patients undergoing one-stop Hybrid coronary revascularization(HCR).
Study Type

Status

Overall Status: Unknown status
Start Date: Jun 2015
Primary Completion Date: Mar 2017Estimated
Completion Date: Apr 2017Estimated

Study Record Dates

First Submitted: Jun 14, 2015
First Submitted that Met QC Criteria: Jul 30, 2015
First Posted: Jul 31, 2015Estimated
Last Update Submitted that Met QC Criteria: Feb 8, 2017
Last Update Posted: Feb 9, 2017Estimated
Last Verified: Feb 2017

NCT06228456Recruiting

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

NCT02052635Terminated

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

NCT02081443Completed

In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients

NCT03078465Withdrawn

Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI

NCT01603082Completed

Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

NCT02330640Completed

A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting